Literature DB >> 28803095

Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study.

Nehal P Vadhan1, Cheryl M Corcoran2, Gill Bedi2, John G Keilp2, Margaret Haney2.   

Abstract

Marijuana use is associated with psychosis, but its effects are understudied in individuals with preexisting risk for psychotic disorders. This preliminary study examined the acute psychological and physiological effects of smoked marijuana (0.0% or 5.5% Δ9-THC) in marijuana users at clinical high-risk (CHR; n = 6) to develop a psychotic disorder, and those not at risk (n = 6), under controlled laboratory conditions. CHR marijuana users exhibited temporary increases in psychotic-like states and decreases in neurocognitive performance during marijuana intoxication but control marijuana smokers did not. These findings, if replicated, may support a psychotogenic role for marijuana in CHR individuals.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Prodromal psychosis; Ultra high-risk

Mesh:

Year:  2017        PMID: 28803095      PMCID: PMC5890804          DOI: 10.1016/j.psychres.2017.07.070

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  22 in total

Review 1.  Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia.

Authors:  David A Lewis; Dianne Cruz; Stephen Eggan; Susan Erickson
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

2.  Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use.

Authors:  Romina Mizrahi; Miran Kenk; Ivonne Suridjan; Isabelle Boileau; Tony P George; Kwame McKenzie; Alan A Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2013-12-24       Impact factor: 7.853

3.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

4.  Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study.

Authors:  H Verdoux; C Gindre; F Sorbara; M Tournier; J D Swendsen
Journal:  Psychol Med       Date:  2003-01       Impact factor: 7.723

Review 5.  Human Laboratory Studies on Cannabinoids and Psychosis.

Authors:  Mohamed Sherif; Rajiv Radhakrishnan; Deepak Cyril D'Souza; Mohini Ranganathan
Journal:  Biol Psychiatry       Date:  2016-02-02       Impact factor: 13.382

6.  Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis.

Authors:  M J McHugh; P D McGorry; A R Yung; A Lin; S J Wood; J A Hartmann; B Nelson
Journal:  Psychol Med       Date:  2016-11-08       Impact factor: 7.723

7.  Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Authors:  Deepak Cyril D'Souza; Mohini Ranganathan; Gabriel Braley; Ralitza Gueorguieva; Zoran Zimolo; Thomas Cooper; Edward Perry; John Krystal
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

8.  Cannabis use and transition to psychosis in people at ultra-high risk.

Authors:  L R Valmaggia; F L Day; C Jones; S Bissoli; C Pugh; D Hall; S Bhattacharyya; O Howes; J Stone; P Fusar-Poli; M Byrne; P K McGuire
Journal:  Psychol Med       Date:  2014-09       Impact factor: 7.723

Review 9.  Association Between Cannabis and Psychosis: Epidemiologic Evidence.

Authors:  Suzanne H Gage; Matthew Hickman; Stanley Zammit
Journal:  Biol Psychiatry       Date:  2015-08-12       Impact factor: 13.382

10.  Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study.

Authors:  Rebecca Kuepper; Jenny Ceccarini; Johan Lataster; Jim van Os; Marinus van Kroonenburgh; Joop M A van Gerven; Machteld Marcelis; Koen Van Laere; Cécile Henquet
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more
  8 in total

1.  Correspondence on Curran et al. (2018): 'Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects'.

Authors:  Nehal P Vadhan; Cheryl M Corcoran; John G Keilp; Margaret Haney
Journal:  Psychol Med       Date:  2019-01-29       Impact factor: 7.723

Review 2.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

3.  Quantifying cannabis: A field study of marijuana quantity estimation.

Authors:  Mark A Prince; Bradley T Conner; Matthew R Pearson
Journal:  Psychol Addict Behav       Date:  2018-05-17

4.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505

5.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

6.  Overbaked: assessing and predicting acute adverse reactions to Cannabis.

Authors:  Emily M LaFrance; Amanda Stueber; Nicholas C Glodosky; Dakota Mauzay; Carrie Cuttler
Journal:  J Cannabis Res       Date:  2020-01-02

7.  Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research.

Authors:  Reilly R Kayser; Margaret Haney; Helen Blair Simpson
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

8.  Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Authors:  Tabea Schoeler; Jason Ferris; Adam R Winstock
Journal:  Transl Psychiatry       Date:  2022-09-06       Impact factor: 7.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.